Clinical Outcome After Saphenous Vein Stenting With Taxus Liberte Stent: Results From the OLYMPIA Registry (TAXUS Liberte Postapproval Global Program)

We evaluated the incidence of clinical events after implantation of the TAXUS Liberte paclitaxel-eluting stent in saphenous vein graft (SVG) lesions in an unselected patient population. The OLYMPIA (TAXUS Liberte Post-Approval Global Registry) program gathered data on 21 954 patients receiving at least 1 TAXUS Liberte stent, including 345 patients with SVG lesions. All cardiac events were monitored with independent adjudication of end points. Patients enrolled at procedure started with no mandated inclusion/exclusion criteria. In SVG-OLYMPIA (n = 345), baseline comorbidities/complex disease were more frequent than the rest of the OLYMPIA (n = 21 560). SVG-OLYMPIA had similar cardiac death, target vessel revascularization, and definitive stent thrombosis rates than the rest of OLYMPIA. Despite higher baseline risk, the SVG-OLYMPIA had similar 12-month clinical outcome than the rest of the OLYMPIA registry, confirming the safety and efficacy of the TAXUS Liberte stent in this high-risk group.